REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)
This study is currently recruiting participants.
Verified April 2013 by University of Glasgow
Sponsor:
University of Glasgow
Collaborators:
NHS Greater Glasgow and Clyde
Juvenile Diabetes Research Foundation
Imperial College London
University of Wisconsin School of Medicine and Public Health
University of Dundee
Merck Serono S.A., Geneva
Itamar-Medical, Israel
University of Western Ontario, Canada
University of Melbourne
Steno Diabetes Center
Maastricht University Medical Center
Information provided by (Responsible Party):
Prof John Petrie, University of Glasgow
ClinicalTrials.gov Identifier:
NCT01483560
First received: November 23, 2011
Last updated: April 1, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The trial is conducted in the UK, Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid IMT, in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for cardiovascular disease.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Mellitus, Type 1 |
Drug: Metformin Drug: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Phase 3 Study of Metformin in Adults With Type 1 Diabetes |
Resource links provided by NLM:
Genetics Home Reference related topics:
type 1 diabetes
MedlinePlus related topics:
Cholesterol
Diabetes
Diabetes Medicines
Diabetes Type 1
Retinal Disorders
U.S. FDA Resources
Further study details as provided by University of Glasgow:
Primary Outcome Measures:
- Change in averaged mean far wall common carotid artery IMT [ Time Frame: 0, 12 months, 24 months, 36 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Change in HbA1c [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]
- Change in LDL Cholesterol [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]
- Change in albuminuria & estimated glomerular filtration rate [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]Number of participants developing new microalbuminuria; change in absolute concentration
- Change in retinopathy stage [ Time Frame: Baseline, Year 3 ] [ Designated as safety issue: No ]ETDRS grade
- Change in weight [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]
- Change in insulin dose [ Time Frame: Baseline, Year 1, Year 2, Year 3 ] [ Designated as safety issue: No ]
- Change in endothelial function [ Time Frame: Baseline, Year 1, Year 3 ] [ Designated as safety issue: No ]RHI units
| Estimated Enrollment: | 500 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | December 2016 |
| Estimated Primary Completion Date: | October 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Metformin
Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
|
Drug: Metformin
3 years treatment duration
Other Name: Glucophage
|
| Placebo Comparator: Placebo |
Drug: Placebo
3 years duration
|
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Type 1 Diabetes for five years or more*
- Age 40 years or above
- 7.0 =< HbA1c <10.0% (53 - 86 mmol/mol)
AND 3 or more of the following ten CVD risk factors:
- BMI >27 kg/m^2
- Current HbA1c >8.0% (64 mmol/mol)
- Known CVD/peripheral vascular disease
- Current smoker
- Estimated glomerular filtration rate <90 ml/min per 1.73 m^3
- Confirmed micro- or macroalbuminuria [according to local assays and reference ranges]
- Hypertension (BP >=140/90mmHg or established on antihypertensive treatment)
- Dyslipidaemia [total cholesterol >=5.0 mmol/L (200 mg/dL);OR HDL cholesterol <1.20 mmol/L (46mg/dL) [MEN]; OR <1.30 mmol/L (50 mg/dL) [WOMEN]; or triglycerides >=1.7 mmol/L (150mg/dL); or established on lipid-lowering treatment)]
- Strong family history of CVD (at least one parent, biological aunt/ uncle, or sibling with myocardial infarction or stroke aged <60 years)
- Duration of diabetes > 20 years
Exclusion Criteria:
- eGFR < 45 ml/min/1.73m2
- woman of childbearing age not on effective contraception
- Pregnancy and/or lactation
- Acute coronary syndrome or Stroke/Transient Ischaemic Attack within the last three months
- NYHA stage 3 or 4 heart failure
- Significant hypoglycaemia unawareness
- Impaired cognitive function/ unable to give informed consent
- Previous carotid surgery/ inability to capture adequate carotid images
- Estimated glomerular filtration < 45ml/min/1.73m^2 (MDRD)
- Gastroparesis
- History of lactic acidosis
- Other contraindications to metformin (hepatic impairment, known hypersensitivity to metformin, acute illness such as dehydration, severe infection, shock, acute cardiac failure or suspected tissue hypoxia)
- Any coexistent life threatening condition including prior diagnosis of cancer within two years
- History of alcohol problem or drug abuse
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01483560
Contacts
| Contact: John Petrie | 00 44 141 330 3325 | john.petrie@glasgow.ac.uk |
Locations
| Australia | |
| St Vincent's Hospital | Recruiting |
| Melbourne, Australia | |
| Contact: Alicia Jenkins jenkinsa@medstv.unimelb.edu.au | |
| Principal Investigator: Alicia Jenkins | |
| Sub-Investigator: David O'Neal | |
| Royal Melbourne Hospital | Recruiting |
| Melbourne, Australia | |
| Contact: Peter Colman peter.colman@mh.org.au | |
| Principal Investigator: Peter Colman | |
| Royal Prince Albert Hospital | Recruiting |
| Sydney, Australia | |
| Contact: Stephen Twigg stwigg@med.usyd.edu.au | |
| Principal Investigator: Stephen Twigg | |
| Canada | |
| St Joseph's Health Care | Recruiting |
| Ontario, Canada | |
| Contact: Irene Hramiak irene.hramiak@sjhc.london.on.ca | |
| Principal Investigator: Irene Hramiak | |
| Ottawa Hospital Riverside Campus | Not yet recruiting |
| Ottawa, Canada | |
| Contact: TC Ooi tcooi@toh.on.ca | |
| Principal Investigator: TC Ooi | |
| Denmark | |
| Steno Diabetes Centre | Not yet recruiting |
| Gentofte, Denmark | |
| Contact: Peter Rossing ltar@steno.dk | |
| Principal Investigator: Peter Rossing | |
| Netherlands | |
| Maastricht University Medical Centre | Recruiting |
| Maastricht, Netherlands | |
| Contact: Coen Stehouwer cda.stehouwer@mumc.nl | |
| Principal Investigator: Coen Stehouwer | |
| Sub-Investigator: Martijn Brouwers | |
| United Kingdom | |
| Aberdeen Royal Infirmary | Not yet recruiting |
| Aberdeen, United Kingdom | |
| Contact: Donald Pearson donald.pearson@nhs.net | |
| Principal Investigator: Donald Pearson | |
| Diabetes Support Unit, Ninewells Hospital and Medical School | Recruiting |
| Dundee, United Kingdom | |
| Contact: Graham Leese graham.leese@nhs.net | |
| Principal Investigator: Graham Leese | |
| University Hospital North Durham | Recruiting |
| Durham, United Kingdom | |
| Contact: Kamal Abouglilia kamal.abouglila@cddft.nhs.uk | |
| Principal Investigator: Kamal Abouglilia | |
| Edinburgh Western Infirmary | Not yet recruiting |
| Edinburgh, United Kingdom | |
| Contact: John McKnight john.mcknight@nhs.net | |
| Principal Investigator: John McKnight | |
| Edinburgh Royal Infirmary | Not yet recruiting |
| Edinburgh, United Kingdom | |
| Contact: Alan Jaap alan.jaap@nhslothian.scot.nhs.uk | |
| Principal Investigator: Alan Jaap | |
| Peninsula NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust | Recruiting |
| Exeter, United Kingdom | |
| Contact: Roderick Warren roderick.warren@nhs.net | |
| Principal Investigator: Roderick Warren | |
| Sub-Investigator: Angela Shore | |
| Stobhill Hospital, Diabetes Clinic | Recruiting |
| Glasgow, United Kingdom | |
| Contact: John Petrie 0044 141 330 3325 john.petrie@glasgow.ac.uk | |
| Principal Investigator: Gerard McKay | |
| Michael White Diabetes Centre, Hull Royal Infirmary | Recruiting |
| Hull, United Kingdom | |
| Contact: Steve Atkin stephen.atkin@hyms.ac.uk | |
| Principal Investigator: Steve Atkin | |
| Clinical Sciences Centre, University Hospital | Not yet recruiting |
| Liverpool, United Kingdom | |
| Contact: John Wilding j.p.h.wilding@liverpool.ac.uk | |
| Principal Investigator: John Wilding | |
| Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College Healthcare NHS Trust | Recruiting |
| London, United Kingdom | |
| Contact: Nick Oliver nick.oliver@imperial.ac.uk | |
| Principal Investigator: Nick Oliver | |
| Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary | Recruiting |
| Manchester, United Kingdom | |
| Contact: Rob Davies rob.davies@cmft.nhs.uk | |
| Principal Investigator: Martin Gibson | |
| Newcastle NIHR Clinical Research Facility, Royal Victoria Hospital | Recruiting |
| Newcastle, United Kingdom | |
| Contact: Mark Walker mark.walker@newcastle.ac.uk | |
| Principal Investigator: Mark Walker | |
| Diabetes Clinical Research Centre, Plymouth | Recruiting |
| Plymouth, United Kingdom | |
| Contact: Ann Millward ann.millward@pms.ac.uk | |
| Principal Investigator: Ann Millward | |
| Sub-Investigator: Mike Eaton | |
| Salford Royal NHS Foundation Trust | Recruiting |
| Salford, United Kingdom | |
| Contact: Martin Gibson martin.gibson@manchester.ac.uk | |
| Principal Investigator: Martin Gibson | |
Sponsors and Collaborators
University of Glasgow
NHS Greater Glasgow and Clyde
Juvenile Diabetes Research Foundation
Imperial College London
University of Wisconsin School of Medicine and Public Health
University of Dundee
Merck Serono S.A., Geneva
Itamar-Medical, Israel
University of Western Ontario, Canada
University of Melbourne
Steno Diabetes Center
Maastricht University Medical Center
Investigators
| Principal Investigator: | John Petrie, Prof | University of Glasgow |
| Study Director: | Helen Colhoun, Prof | University of Dundee |
More Information
No publications provided
| Responsible Party: | Prof John Petrie, Clinical Professor in Diabetic Medicine, University of Glasgow |
| ClinicalTrials.gov Identifier: | NCT01483560 History of Changes |
| Other Study ID Numbers: | GN10DI406, 2011-000300-18 |
| Study First Received: | November 23, 2011 |
| Last Updated: | April 1, 2013 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency United Kingdom: National Health Service Canada: Canadian Institutes of Health Research Australia: National Health and Medical Research Council Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) Denmark: Danish Medicines Agency |
Keywords provided by University of Glasgow:
|
REMOVAL metformin carotid IMT LDL Cholesterol |
endothelial function retinopathy HbA1c |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases |
Immune System Diseases Metformin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013